No Data
No Data
Guangdong Silver Age Sci & Tech Co.,Ltd. (SZSE:300221) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Guangdong Silver Age Sci&Tech,Co.,Ltd. (300221.SZ): Beta-nicotinamide mononucleotide related products are not the strategic direction of HingBio.
Guangdong Silver Age Sci&Tech,Co.,Ltd. (300221.SZ) stated on the investor interaction platform on September 11th that the company's affiliated company, Dongguan Jinghang New Materials Investment Partnership (limited partnership), has invested in Suzhou Yinghang Biotechnology Co., Ltd., which is mainly engaged in the research and development, production, and sales of industrial biotechnology and products in the fields of pharmaceutical health, animal nutrition, animal health, and plant protection. β-nicotinamide mononucleotide-related products are not the strategic direction of Yinghang Biotechnology, and there has been no progress in the development of related products.
Guangdong Silver Age Sci&Tech,Co.,Ltd. (300221.SZ) does not directly provide products to Huawei.
Guangdong Silver Age Sci&Tech,Co.,Ltd. (300221.SZ) stated on the investor interaction platform on September 5th that the company does not directly provide products for Huawei, but supplies products for its supply chain. The main products supplied are flame retardant and spray-free materials.
Guangdong Silver Age Sci&Tech,Co.,Ltd.: Summary of Half-Year Report in 2024.
Guangdong Silver Age Sci&Tech,Co.,Ltd.: Half-year report for the year 2024.
Guangdong Silver Age Sci&Tech,Co.,Ltd.(300221.SZ): The net income attributable to the parent in the first half of the year was 26.1934 million yuan, a year-on-year increase of 60.87%.
Guangdong Silver Age Sci&Tech,Co.,Ltd. (300221.SZ) announced its 2024 half-yearly report. During the reporting period, the company achieved a revenue of 0.875 billion yuan, an increase of 14.94% compared to the same period last year. Both categories of the company's products saw growth in revenue, with modified plastic products increasing by 13.47% and Asia Vets-related products increasing by 17.77% compared to the same period last year. During the reporting period, the company achieved an operating profit of 0.028 billion yuan, a year-on-year increase of 69.98%. The net income attributable to the shareholders of the listed company was 26.1934 million yuan, an increase of 60.87% compared to the same period last year.
No Data
No Data